Back to search

Peptide record

TPDB09890

Antibacterial Anticancer Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09890
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
RFCVYAYVRVRGVLVRYRRCF
Physicochemical Analysis
C123H193N39O25S2
NDEQHIKMPSTW
R
2682.25
11.11
6
0
12
+6
-1.07
0.281
92.38
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
4595
171.31
5
Residue Composition
number
1
A
6
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
0
I
1
L
0
K
0
M
2
F
0
P
0
S
0
T
0
W
3
Y
5
V
Amino Acid Distribution
A: 1 R: 6 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 0 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 3 V: 5
Chemical Descriptors
21
C123H193N39O25S2
2682.25
11.11
+6
-1.07
0.281
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
1 µM

Target

E.coli ML35p or ATCC 25922 or M15

Source & Reference

NA

Other

active against Gram- E.coli ML35p or ATCC 25922 or M15 (MIC 1 uM), P. aeruginosa ATCC 27853 or clinical c.i. (MIC 1-2 uM), A. baumanii c.i. (MIC 2 uM), Gra
Evidence 2 Activity

Activity

MIC
Antibacterial
2 µM

Target

L. monocytogenes EGD

Source & Reference

NA

Other

. aeruginosa ATCC 27853 or clinical c.i. (MIC 1-2 uM), A. baumanii c.i. (MIC 2 uM), Gram+ L. monocytogenes EGD (MIC 2 uM), S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i. (MIC 2-4 uM), S. interm
Evidence 3 Activity

Activity

MIC
Antibacterial
4 µM

Target

S. intermidius

Source & Reference

NA

Other

MIC 2 uM), S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i. (MIC 2-4 uM), S. intermidius (MIC 4 uM).
Evidence 4 Activity

Activity

15% Hemolysis
Toxicity
10.6 µM
Hemolytic Cytotoxic
15% Hemolysis | 10.6 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 5 Activity

Activity

50% Hemolysis
Toxicity
60.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 60.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 6 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Mar Drugs. 2019 Jun 23 17(6):376.
Evidence 7 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis